ALPMF News and Press, Astellas Pharma Inc From 08/21/20

Astellas Pharma ( OTCPK:ALPMF ) unit Audentes Therapeutics reports the third death in its Phase 1/2 ASPIRO study evaluating gene therapy AT132 in patients with X-linked myotubular myopathy , a rare serious and life-threatening inherited disorder characterized by weakness in the skeletal...

Original post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Astellas Pharma Inc (ALPMF) Q1 2021 Earnings Conference Call August 04, 2020 3:00 AM ET Company Participants Naoki Okamura – Representative Director and Executive Vice President Mike Kitagawa – Senior Vice President of Development Project Management Yukio Matsui &#x...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q1 earnings Read more ...

Astellas Pharma ( OTCPK:ALPMF ) : Q1 GAAP EPS of ¥27.12. More news on: Astellas Pharma Inc., Astellas Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...

Kiniksa Reports Positive Outcome from 28-Day Clinical Trial Kiniksa Pharmaceuticals Ltd. ( KNSA ) announced that it has received positive data from its COVID-19 treatment trial. This 28 day clinical outcomes data pertains to the open label treatment protocol with mavrilimumab. The compan...

Astellas Pharma ( OTCPK:ALPMF ) announces positive results from a Phase 3 clinical trial, DOLOMITES , evaluating roxadustat for the treatment of anemia in non-dialysis-dependent adults with stage 3-5 chronic kidney disease. The data were virtually presented at the European Renal Associati...

Japan's Ministry of Health, Labor and Welfare approves Astellas Pharma's ( OTCPK:ALPMF ) Xtandi (enzalutamide) for the treatment of prostate cancer patients with distant metastases. More news on: Astellas Pharma Inc., Pfizer Inc., Astellas Pharma Inc., Healthcare stocks news, Read mo...